美国MediciNova
MediciNova ，公司是一家公开上市的生物制药公司，侧重于获取和发展新的，小分子疗法，用于治疗疾病的未满足的需要特别关注美国市场。通过战略联盟与日本主要的制药公司， MediciNova拥有权，多元化的投资组合的临床和临床前候选产品，每个MediciNova认为有一个良好的特点和不同的治疗资料，有吸引力的商业潜力和专利资产的说法有充分的商业范围。 MediciNova的管道包括6个临床阶段的化合物，用于治疗急性加重哮喘，多发性硬化症，哮喘，间质性膀胱炎，固体肿瘤的癌症，广泛性焦虑症，早产和尿失禁和前两个阶段的化合物，用于治疗血栓性疾病。 MediciNova目前的战略是集中资源，它的两个优先候选产品，美国明尼苏达- 221用于治疗急性加重哮喘和Mn - 166用于治疗多发性硬化症，要么追求发展独立的，如果锰- 221 ，或建立战略合作，以支持进一步发展，如锰166 。 MediciNova将寻求其他产品赚钱候选人键值拐点。

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus its resources on its two prioritized product candidates, MN-221 for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations and MN-166 for the treatment of multiple sclerosis, and either pursue development independently, in the case of MN-221, or establish a strategic collaboration to support further development in the United States, in the case of MN-166. MediciNova will seek to monetize its other product candidates at key value inflection points. MediciNova’s executive management team has extensive global development, regulatory and commercial experience, and manages its international clinical and manufacturing operations through efficient and cost-effective utilization of contract research organizations. Headquartered in San Diego, California, MediciNova today has approximately 25 employees.